All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.

2017-08-07T10:16:14.000Z

Five-year follow-up of ABVD + brentuximab vedotin, or AVD + brentuximab vedotin in the treatment of advanced cHL

Aug 7, 2017
Share:

Bookmark this article

In a letter to the editor of Blood published online in July ahead of print, Joseph M. Connors, of the British Columbia Cancer Agency Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, Canada, and colleagues presented five-year follow-up data on the use of Brentuximab Vedotin (BV) in combination with ABVD or AVD in a cohort of 51 previously untreated advanced stage classical Hodgkin Lymphoma patients. In the previously reported data set from this study it was concluded that the addition of BV to ABVD in HL patients resulted in ‘excessive pulmonary toxicity’ when compared to patients being treated with this combination, but without bleomycin2. A follow-up study was therefore instigated to determine the longer-term safety and efficacy data comparing BV with either ABVD or AVD.

Key Highlights:

  • Previous study:
    • 51 pts recruited: 25 pts received ABVD+BV, 26 pts received AVD+BV
    • Dosing:
      • BV every two weeks, with dose escalation from 0.6 mg/kg to 1.2 mg/kg (I.V.)
      • In the AVD group, all patients started at 1.2 mg/kg BV (I.V.)
    • In the ABVD group, two patients died from pulmonary toxicity, and one withdrew consent
  • This study:
  • 48 pts included in five-year follow-up: 22 pts who received ABVD+BV, 26 pts who received AVD+BV
  • Median follow-up = 66 months (45 – 84 months)
  • Pts who relapsed: ABVD+BV = 3/22, AVD+BV = 2/26. All relapsing pts had HD chemotherapy and AutoSCT with four being in second remission
  • No further deaths reported, one patient with secondary relapse receiving palliative care
  • Efficacy at five-years follow-up:
    • Failure Free Survival: ABVD+BV = 79%, AVD+BV = 92%
    • OS: ABVD+BV = 92%, AVD+BV = 100%
  • However, there was some disparity between the International Prognostic Scores (IPS) between groups which was not commented upon. IPS 4–7 accounted for 80% of the ABVD+BV group (20/25), but only 54% of the AVD+BV group (14/26)

In conclusion, the authors stated that the combination of AVD+BV is safe, and results in ‘excellent and durable control’ of cHL. The authors also state that the possible superiority of the combination of AVD+BV compared with ABVD alone is being assessed in the ECHELON trial.

Abstract: N/A

  1. Connors J.M. et al. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced stage classical Hodgkin lymphoma. Blood. 2017 Jul. [ePub ahead of print 2017 July 21]. DOI: https://doi.org/10.1182/blood-2017-05-784678.
  2. Younes A. et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncology.2013 Dec;14(13):1348-56. DOI: 10.1016/S1470-2045(13)70501-1.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
26 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox